These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Experimental study on the antituberculous activity of ofloxacins].
    Author: Duan L, Liang G, Li H.
    Journal: Zhonghua Jie He He Hu Xi Za Zhi; 1997 Apr; 20(2):98-100. PubMed ID: 10072834.
    Abstract:
    OBJECTIVE: To compare the antituberculous activities of ofloxacins (OFLX) made by different pharmaceutical companies. METHODS: The minimal inhibitory concentrations (MIC) of OFLX were determined by two-fold dilution method. The efficacy of OFLX was compared in terms of median survival time (ST50) against M. tuberculosis infection in mice. RESULTS: In vitro the activities against M. tuberculosis (H37Rv), M. bovis (Ravenel) and M. Phlei products showed similar degree. The MICs of OFLX were 0.5-1.0 microgram/ml in modified Sauton medium and 1.0 microgram/ml in modified Lowenstin-Jensen medium. OFLX was more active than ethambutol (MIC 4-8 micrograms/ml, 2.0 micrograms/ml, respectively) against M. tuberculosis in the same media. OFLX from domestic or foreign drug companies showed similar results for treating M. tuberculosis infection in mice and all were significantly effective. The efficacy of OFLX at the dose of 4 mg per mouse was found close to that of ethambutol (EMB) at the dose of 2 mg per mouse. The efficacy of OFLX at the dose of 2 mg per mouse close to EMB at the dose of 1 mg per mouse and thiacetazone at the dose of 2 mg per mouse. CONCLUSIONS: In vitro and in vivo, the activities of OFLX from different sources against M. tuberculosis are about the same.
    [Abstract] [Full Text] [Related] [New Search]